Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Cells can sense and mend damaged DNA caused by certain chemotherapy drugs. Researchers discovered a previously unknown repair complex that targets this type of damage. This finding could lead to more effective chemotherapy treatments by amplifying the killing power of existing drugs.
Researchers have developed a new platform for assessing anti-cancer drug efficacy in lung cancer, reducing attrition rates and increasing success of drugs. The 'explants' approach involves analyzing tumor tissue samples taken from patients immediately after surgery, providing patient-relevant data.
A comprehensive study from the Keck School of Medicine of USC found that IUD use is associated with a dramatic decrease in cervical cancer incidence. The analysis included data from 16 high-quality observational studies involving over 12,000 women worldwide.
Researchers discover that CDK8 plays a critical role in allowing cancer cells to use glucose for energy. Blocking CDK8 activity combined with glycolysis inhibitors slows cancer cell growth more effectively than either approach alone.
Researchers develop a new strategy for treating cancer by controlling chromatin packing densities, which determines gene expression and resistance to treatment. The approach has shown promising results in cellular cultures and is now being tested in animal models.
Current RECIST guidelines face challenges in measuring cancer response with emerging targeted therapies. Researchers propose a new baseline approach to track stability and separate tumor burden from treated areas.
A new study reveals that non-small cell lung cancers are driven by multiple genetic changes, including alterations in TP53 and other pathways. The findings suggest that combination therapies targeting these mutations may improve treatment outcomes and prevent drug resistance.
Researchers synthesized 30 flavanone derivatives to target NF-kappaB, identifying compounds with potent anti-inflammatory and cytotoxic activities against various cancer cell lines. The top-ranked compounds exhibited improved pharmacological profiles through conjugation of two pharmacophores.
Experts say pre-menopausal women with hormone-dependent advanced breast cancer should be included in clinical trials alongside older women. This could provide valuable insights into the best treatments for these patients, who make up a third of all advanced breast cancer cases globally.
Researchers have identified a connection between the PI3K pathway and telomere protection, revealing a potential target for cancer treatment. Inhibition of PI3K reduces TRF1 levels, leading to chromosome destabilization and cancer cell death.
Researchers developed a new three-step system targeting and eliminating colorectal cancer using nuclear medicine. The treatment achieved a 100-percent cure rate in mouse models without toxic effects.
Researchers at ITMO University have developed a novel approach to obtaining non-toxic magnetic photonic crystals, expanding their applications from photonics to biomedicine. These nanospheres can be used to design drugs for fighting thrombosis and cancer, and their biocompatibility makes them suitable for targeted drug delivery.
Researchers developed a way to control polymer molecule shape, leading to non-spherical nanoparticles that can encapsulate drugs. These natural-shaped plastic nanoparticles have shown preliminary evidence of entering tumor cells more easily than spherical ones.
Researchers mapped genetic alterations in normal mammary duct cells, identifying early changes that precede tumour development. This study provides new insights into breast cancer biology and may lead to more precision in screening and prevention.
The alisertib and TAK-228 combination shows promise in treating solid tumors, particularly triple-negative breast cancer. In a phase 1 clinical trial, the treatment was generally well-tolerated, with patients experiencing fatigue and decreased neutrophil count as common side effects.
Researchers investigate how gut bacteria metabolize chemotherapy drug irinotecan, finding that certain individuals are more likely to experience severe side effects. The study suggests analyzing patients' microbiomes before treatment could predict and prevent adverse reactions.
The Lancet Oncology Commission recommends prioritizing key areas for US$2 billion funding to advance cancer research and treatment, focusing on prevention, targeted interventions, and patient-centered data sharing. The report aims to improve cancer care for underserved groups and reduce health disparities.
A new open-source machine learning program at Georgia Tech predicts cancer drug effectiveness via genetic data, reducing human bias and increasing accuracy. The program aims to be widely used by researchers to improve treatment outcomes.
A new test targeting cancer drug effectiveness has been identified using protein HER3 levels, helping doctors tailor treatment for patients. The test shows that patients with high HER3 levels benefit from the drug, while those with low levels experience no effect, providing a more personalized approach to bowel cancer treatment.
A recent study by TGen-USC reveals that Precision Medicine in oncology is less precise for individuals with Latin American, African and Asian ancestry. A new genomic tool called LumosVar has been developed to help identify genetic variants, but more research is needed to overcome population differences.
Scientists have found that a rare genetic disease known as NGLY1 deficiency could hold the key to understanding resistance to cancer drugs. Dampening this enzyme may allow proteasome inhibitors to continue killing cancer cells, providing hope for new treatments.
A new class of antibody-drug conjugates, dubbed dual variable domain antibodies (DVD-ADCs), have been developed using a versatile double-decker technology. These pharmaceuticals selectively deliver drugs to cancer cells without harming healthy cells and tissues.
Scientists have successfully synthesized a promising anticancer molecule, BE-43547A(2), which shows unprecedented activity against pancreatic cancer stem cells. The compound reduces cancer stem cell proliferation by 21-fold and abolishes tumor-initiating capability.
Researchers have developed a new medicine, tarloxitinib, that brings high doses of anti-EGFR drugs to tumors while keeping toxic levels in healthy tissues. The prodrug-based approach has shown promising results in tests against lung cancer cells with EGFR exon 20 insertions.
A new analysis from the RAND Corporation estimates that biosimilar drugs could reduce healthcare spending in the US by $54 billion over the next decade. This is largely due to increased competition and regulatory changes, which will drive down prices and improve access to biologic drugs.
A survey of young white women found that over one in five have signs of indoor tanning addiction and three times more likely to meet criteria for dependence. Women with depression were most likely to weigh benefits against risks.
Researchers found that nerves stimulate the formation of new blood vessels that promote tumor growth in prostate cancer. They discovered an "angio-metabolic switch" triggered by norepinephrine binding to endothelial cells, which changes how cells metabolize glucose, favoring glycolysis.
A rare cancer in patients with breast implants, BIA-ALCL, may be on the rise and underreported. The cancer is linked to textured implants, which were introduced in the 1990s, and can lead to chronic inflammation and lymphoma, resulting in a good prognosis when treated promptly.
Researchers at the Francis Crick Institute have identified a novel protein that exclusively targets Wnt signalling in tumour cells, reducing growth of colon cancer cells without harming healthy cells.
Researchers found that high genetic diversity can prime new mutations causing drug resistance in yeast cells, with varying degrees of impact. The study highlights the importance of understanding genetic diversity's role in evolving drug resistance, with potential implications for treating antimicrobial and anticancer diseases.
The collaboration aims to establish a PDX Data Commons and Coordinating Center to integrate and share PDX treatment data for research. This will enhance precision in measuring drug-response and provide a clinical trial roadmap for piloting treatments.
Scientists at Wake Forest Baptist will use a $9.2 million grant to develop new molecularly targeted drugs and drug delivery systems for aggressive brain cancer glioblastoma. The goal is to directly attack tumor mass and cells in surrounding areas, increasing therapeutic efficacy.
A new AI model called druGAN enables the generation of novel molecules with desired properties, surpassing previous GAN-based approaches. The model uses reinforcement learning to generate effective molecular graphs, paving the way for improved pharmaceuticals.
A new study by American Cancer Society investigators finds workers at organizations with fewer than 25 employees are less likely to have been screened for three cancers. After adjusting for socioeconomic factors and insurance status, most of the difference in screening rates disappears.
Stanford researchers have found a new method to create bryostatin, a compound with potential for treating cancer, Alzheimer's disease, and HIV. The new synthetic supply will allow ongoing trials to continue testing its effectiveness.
The Van Andel Research Institute has been awarded two grants totaling $5.5 million to pursue clinical trials of epigenetic drugs combining with immunotherapies to enhance tumor response. The trials aim to test whether epigenetic therapies can reverse resistance to immunotherapy in lung and bladder cancers.
Researchers successfully deliver platinum-based chemotherapy drugs via nanoparticles to treat nonmuscle-invasive bladder cancer, reducing systemic absorption and toxicity. The study offers a potential less toxic clinical alternative to standard chemotherapy.
Researchers from Wellcome Trust Sanger Institute and Royal National Orthopaedic Hospital NHS Trust suggest a clinical trial of PI3K inhibitors for chordoma patients with specific genetic mutations. The study provides promising new treatment options for a rare and aggressive form of bone cancer.
Researchers at Dana-Farber Cancer Institute discovered a protein called Bclw that protects nerves from degeneration. Adding Bclw to nerve axons before exposure to chemotherapy drugs may prevent peripheral neuropathy symptoms.
The University of Houston and MD Anderson are launching a program to create a more diverse pool of medical doctors and scientists. The U-HAND Program aims to address racial and ethnic disparities in the healthcare workforce and health outcomes.
Researchers have developed a new class of drugs called PARP inhibitors to treat ovarian cancer by targeting synthetic lethality. These drugs aim to kill cancer cells by exploiting their genetic vulnerabilities, offering new hope to those with limited treatment options.
Researchers found that ceritinib, an FDA-approved drug for ALK-rearranged non-small cell lung cancer, also inhibits previously unknown targets. The study shows promise for repurposing the drug to target other cancers with networked alterations.
Researchers found that neratinib can block the function of Ras oncogenes through an unexpected process, killing non-small cell lung cancer cells resistant to afatinib. The study also discovered that neratinib triggers a seismic event in the plasma membrane, rapidly reducing expression of mutated K- and N-Ras genes.
Many opioid dosage combinations have no prescribing restrictions under Medicare formulary, suggesting an opportunity to limit opioid prescribing. Restricting coverage for prescription drugs is one strategy to decrease opioid prescribing.
A study published in Genome Research investigated the role of p53 in tumor suppression and found that no single gene serves as a backup 'second in command' to activate its functions. Instead, p53 relies on a multifunctional team of genes contributing to tumor suppression.
Researchers found that a protein named ZATT can eliminate DPCs with the help of another protein TDP2. Understanding how TDP2 and ZATT work together may improve cancer patient health outcomes. The discovery could lead to development of new drugs targeting these defenses.
A precision medicine trial is helping doctors target the genetic makeup of high-risk neuroblastoma tumors. Victoria Thompson, a two-year-old girl, is part of the trial and has seen promising results after innovative treatments.
New research explains why mTOR inhibitors can't fully eliminate cancer cells. The drugs target a cell regulator called mTOR, which controls mitochondrial structure and function, ultimately protecting cells from death.
Most new cancer drugs fail to extend or improve patient life, with many approved on surrogate measures. Only 51% of cancer indications showed survival or quality of life gains after a median 5 years on the market. This raises concerns about regulatory standards and the need for rigorous testing.
Researchers at Georgetown University Medical Center discovered a novel agent YK-4-279 that, when combined with vincristine, halts the ability of Ewing sarcoma to grow and progress. The combination produces a microtubule catastrophe in cancer cells, targeting their ability to divide and multiply.
The approved gene therapy Kymriah offers hope for children and young adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. However, its high cost and limited accessibility pose significant challenges for policy-makers and patients alike.
Researchers found that patients with high numbers of alterations detected in their DNA collected from blood samples had a higher response rate to treatment, and median survival was longer. The study suggests that counting mutations in the bloodstream could help predict response to checkpoint inhibitor therapy.
A recent study suggests that switching from cigarette smoking to vaping can lead to significant gains in life expectancy. Researchers estimate that around 6.6 million cigarette smokers could live substantially longer with e-cigarettes over a ten-year period.
A study found that mutations in the KEAP1 gene make lung adenocarcinoma cells vulnerable to oxidative stress, allowing an experimental drug called CB-839 to stop tumor growth. The discovery could lead to a more effective treatment for patients with combined KRAS and KEAP1 mutations.
Researchers at UTSA are developing new cancer drugs from complex natural products with proven anticancer potential. The team aims to recreate the active portion of these compounds to overcome drug resistance and tackle advanced-stage cancers.
Researchers at DGIST have synthesized metal-reactive oxygen species that react with nitrile, a triple-bonded carbon and nitrogen compound. This discovery could lead to the development of anti-cancer prodrugs.
Researchers used a proteomics platform to identify proteins with reactive cysteines in non-small-cell lung cancer cells, which could be targeted by drugs. The study found that targeting the protein NR0B1 reduced abnormal growth in NRF2-activated lung cancers.
Scientists have identified 10 distinct diseases in deadly childhood brain tumours, each with unique genetic faults. The study found that some types can be treated using existing drugs or those under development, offering hope for more effective care.
Research shows carbidopa, an FDA-approved Parkinson's disease drug, has anticancer properties. The study found that carbidopa significantly inhibits cancer cell growth in both human pancreatic cancer cells and mouse models, suggesting potential as an anticancer medication.
Researchers at Osaka University discovered that ivermectin, a medication for parasitic infections, also has an anti-tumor effect on epithelial ovarian cancer (EOC) cells. The gene target KPNB1 was identified as having oncogenic properties, and its inhibition induced apoptosis in EOC cells.